Kirk Nelson

1.6k total citations
23 papers, 1.2k citations indexed

About

Kirk Nelson is a scholar working on Molecular Medicine, Molecular Biology and Pollution. According to data from OpenAlex, Kirk Nelson has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Medicine, 10 papers in Molecular Biology and 9 papers in Pollution. Recurrent topics in Kirk Nelson's work include Antibiotic Resistance in Bacteria (20 papers), Pharmaceutical and Antibiotic Environmental Impacts (9 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Kirk Nelson is often cited by papers focused on Antibiotic Resistance in Bacteria (20 papers), Pharmaceutical and Antibiotic Environmental Impacts (9 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Kirk Nelson collaborates with scholars based in United States and Thailand. Kirk Nelson's co-authors include Debora Rubio-Aparicio, Dongxu Sun, Michael N. Dudley, Ruslan Tsivkovski, Olga Lomovskaya, David C. Griffith, Olga Lomovskaya, Maxim Totrov, Mark L. Cunningham and Karen Joy Shaw and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

Kirk Nelson

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kirk Nelson United States	16	905	555	320	266	218	23	1.2k
Sachin Bhagwat India	19	638 0.7×	530 1.0×	227 0.7×	220 0.8×	190 0.9×	47	1.0k
Ruslan Tsivkovski United States	15	890 1.0×	522 0.9×	205 0.6×	250 0.9×	222 1.0×	16	1.0k
Catherine L. Tooke United Kingdom	13	822 0.9×	371 0.7×	371 1.2×	246 0.9×	137 0.6×	19	1.2k
Debora Rubio-Aparicio United States	15	939 1.0×	600 1.1×	182 0.6×	297 1.1×	238 1.1×	20	1.1k
Haris Jahić United States	10	810 0.9×	503 0.9×	295 0.9×	262 1.0×	147 0.7×	13	994
Thomas F. Durand-Réville United States	16	795 0.9×	445 0.8×	252 0.8×	236 0.9×	137 0.6×	20	1.1k
Corey Fyfe United States	12	510 0.6×	304 0.5×	235 0.7×	162 0.6×	135 0.6×	16	840
Ronald E. Painter United States	14	566 0.6×	347 0.6×	275 0.9×	101 0.4×	125 0.6×	14	970
Takafumi Sato Japan	15	1.5k 1.7×	1.0k 1.9×	433 1.4×	354 1.3×	412 1.9×	34	1.9k
Melissa D. Barnes United States	16	777 0.9×	490 0.9×	182 0.6×	255 1.0×	193 0.9×	22	928

Countries citing papers authored by Kirk Nelson

Since Specialization

Citations

This map shows the geographic impact of Kirk Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk Nelson more than expected).

Fields of papers citing papers by Kirk Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk Nelson. The network helps show where Kirk Nelson may publish in the future.

Co-authorship network of co-authors of Kirk Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk Nelson. A scholar is included among the top collaborators of Kirk Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk Nelson. Kirk Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hudkins, Robert L., Eric Allen, Isaac Hoffman, et al.. (2024). Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia. Journal of Medicinal Chemistry. 67(18). 16737–16756. 10 indexed citations

Lomovskaya, Olga, Mariana Castanheira, Debora Rubio-Aparicio, et al.. (2023). In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales. Antimicrobial Agents and Chemotherapy. 67(11). e0044023–e0044023. 30 indexed citations

Sun, Dongxu, Ruslan Tsivkovski, Joe Pogliano, et al.. (2022). Intrinsic Antibacterial Activity of Xeruborbactam In Vitro : Assessing Spectrum and Mode of Action. Antimicrobial Agents and Chemotherapy. 66(10). e0087922–e0087922. 29 indexed citations

Lomovskaya, Olga, Debora Rubio-Aparicio, Kirk Nelson, et al.. (2021). In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 65(6). 21 indexed citations

Nelson, Kirk, Debora Rubio-Aparicio, Dongxu Sun, Michael Dudley, & Olga Lomovskaya. (2020). In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms. Antimicrobial Agents and Chemotherapy. 64(8). 37 indexed citations

Hecker, Scott J., K. Raja Reddy, Olga Lomovskaya, et al.. (2020). Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases. Journal of Medicinal Chemistry. 63(14). 7491–7507. 158 indexed citations

Lomovskaya, Olga, Kirk Nelson, Debora Rubio-Aparicio, et al.. (2020). Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in Enterobacteriaceae , Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 64(6). 36 indexed citations

Nelson, Kirk, Debora Rubio-Aparicio, Ruslan Tsivkovski, et al.. (2020). In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 64(11). 18 indexed citations

Lomovskaya, Olga, Kirk Nelson, & Debora Rubio-Aparicio. (2019). 727. Potency of the β-Lactamase Inhibitor QPX7728 Is Minimally Affected by KPC Mutations that Reduce Potency of Ceftazidime–Avibactam. Open Forum Infectious Diseases. 6(Supplement_2). S326–S326. 1 indexed citations

10.

Lomovskaya, Olga, Dongxu Sun, Debora Rubio-Aparicio, et al.. (2018). Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii. International Journal of Antimicrobial Agents. 52(3). 404–406. 15 indexed citations

11.

Sun, Dongxu, Debora Rubio-Aparicio, Kirk Nelson, Michael N. Dudley, & Olga Lomovskaya. (2017). Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 61(12). 137 indexed citations

12.

Nelson, Kirk, Peera Hemarajata, Dongxu Sun, et al.. (2017). Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. Antimicrobial Agents and Chemotherapy. 61(10). 137 indexed citations

13.

Lomovskaya, Olga, Mariana Castanheira, Keith S. Kaye, et al.. (2017). Assessment of MIC Increases with Meropenem-Vaborbactam and Ceftazidime-Avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections). Open Forum Infectious Diseases. 4(suppl_1). S540–S540. 8 indexed citations

14.

Lomovskaya, Olga, Kirk Nelson, Debora Rubio-Aparicio, et al.. (2016). Minocycline (MINO) Activity Is Enhanced by Polymyxin B (PmB) in TetB Containing Isolates of Acinetobacter baumannii (ACB), Including Those Resistant to PmB. Open Forum Infectious Diseases. 3(suppl_1). 4 indexed citations

15.

Lomovskaya, Olga, Dongxu Sun, Debora Rubio-Aparicio, Kirk Nelson, & Michael N. Dudley. (2016). TetB Testing and Its Absence Identifies Minocycline (MINO) Susceptible Isolates of Acinetobacter baumannii (ACB). Open Forum Infectious Diseases. 3(suppl_1). 3 indexed citations

16.

Hilgers, M.T., Mark L. Cunningham, Bryan P. Kwan, et al.. (2014). Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines. Journal of Medicinal Chemistry. 57(3). 651–668. 66 indexed citations

17.

Cunningham, Mark L., Bryan P. Kwan, Kirk Nelson, Daniel C. Bensen, & Karen Joy Shaw. (2013). Distinguishing On-Target versus Off-Target Activity in Early Antibacterial Drug Discovery Using a Macromolecular Synthesis Assay. SLAS DISCOVERY. 18(9). 1018–1026. 31 indexed citations

18.

Bensen, Daniel C., Xiaoming Li, Zhiyong Chen, et al.. (2012). Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activity. Bioorganic & Medicinal Chemistry Letters. 23(5). 1537–1543. 58 indexed citations

19.

Li, Xiaoming, M.T. Hilgers, Mark L. Cunningham, et al.. (2011). Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines. Bioorganic & Medicinal Chemistry Letters. 21(18). 5171–5176. 50 indexed citations

20.

Tari, Leslie W., Isaac Hoffman, Daniel C. Bensen, et al.. (2006). Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(3). 688–691. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact